Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The role of amino-acid PET in the light of the new WHO classification 2016 for brain tumors.

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of... - 1 Sept 2018

Suchorska Bogdana, Albert Nathalie L, Bauer Elena K, Tonn Jörg-Christian, Galldiks Norbert

Abstract excerpt

Since its introduction in 2016, the revision of the World Health Organization (WHO) classification of central nervous system tumors has already changed the diagnostic and therapeutic approach in glial tumors. Blurring the lines between entities formerly labelled as "high-grade" or "low-grade", molecular markers define distinct biological subtypes with different clinical course. This new classification raises the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acids
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Positron-Emission Tomography

Share to World Health Organization

Source

Identifiers

PMID: 29696947
DOI: 10.23736/S1824-4785.18.03090-X

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The role of amino-acid PET in the light of the new WHO classification 2016 for brain tumors.PMID 29696947Read ↗

Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas.Semantic proximity Read ↗

Diagnostic Performance of [11C]Methionine Positron Emission Tomography in Newly Diagnosed and Untreated Glioma Based on the Revised World Health Organization 2016 Classification.Semantic proximity Read ↗

Characteristics of [18F]FET PET and MRI in isocitrate dehydrogenase (IDH)-mutant gliomas diagnosed according to the WHO 2021 classification - a retrospective analysis.Semantic proximity Read ↗

The Clinical Utility of Molecular Imaging Using Nuclear Medicine Tools in the Management of All Stages of Adult GliomasSemantic proximity Read ↗

Non-invasive metabolic imaging of brain tumours in the era of precision medicine.Semantic proximity Read ↗

Imaging Findings of New Entities and Patterns in Brain Tumor: Isocitrate Dehydrogenase Mutant, Isocitrate Dehydrogenase Wild-Type, Codeletion, and MGMT Methylation.Semantic proximity Read ↗

IDH mutation is paradoxically associated with higher 18F-FDOPA PET uptake in diffuse grade II and grade III gliomas.Semantic proximity Read ↗

Molecular PET imaging: Unlocking the secrets of cancer metabolismSemantic proximity Read ↗

Biology, genetics and imaging of glial cell tumoursSemantic proximity Read ↗

Screening of targets related to amino acid metabolism in glioma to identify the tumor-promoting effects of its core gene ASLSemantic proximity Read ↗

11 C-Acetate PET/CT for Reactive Astrogliosis Outperforms 11 C-Methionine PET/CT in Glioma Classification and Survival Prediction.Semantic proximity Read ↗

Imaging biomarkers for detecting IDH mutations and monitoring response to novel targeted therapies: Current insights and future perspectives.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.